Cybin inc. reports fiscal year 2023 financial results and recent business highlights

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today reported audited financial results for its fiscal year ended march 31, 2023, and recent business highlights. “during the past year, we have made significant progress advancing our two lead clinical programs, cyb003 and cyb004. we expect.
CYBN Ratings Summary
CYBN Quant Ranking